title: An experimental model for measuring middle ear antimicrobial drug penetration in otitis media.
abstract: Bacteria are an important cause of acute otitis media and successful treatment depends on achieving inhibitory or bacteriacidal antimicrobial drug concentrations in the middle ear. To evaluate further otitis media treatment success and failure, we developed a chinchilla model to study antimicrobial drug penetration through the middle ear mucosa. Using quantitative histomorphometry, we measured the middle ear space in 10 chinchillas and found a mean +/- SD volume of 2.09 +/- 0.08 ml and a mean +/- SD surface area of 14.41 +/- 1.48 cm2. To measure the apparent rate constant (Kc) of antibiotic elimination from the middle ear, through the middle ear mucosa, an antibiotic solution was inoculated into the middle ear cavity, and samples were aspirated between 1 and 8 hr later. In normal ears, the mean Kc +/- SD for amoxicillin was 0.118 +/- 0.013 hr-1, that for a trimethoprim 0.461 +/- 0.090 hr-1, and that for sulfamethoxazole 0.265 +/- 0.062 hr-1. In ears inoculated with type 7F Streptococcus pneumoniae to induce acute otitis media, the Kc +/- SD increased for all three drugs (P less than 0.05): amoxicilin to 0.286 +/- 0.089 hr-1, trimethoprim to 0.662 +/- 0.118 hr-1, and sulfamethoxazole to 0.411 +/- 0.056 hr-1. These values demonstrate that amoxicillin had the lowest apparent penetration rate constant of the three antibiotics but the greatest increase from normal to infected mucosa (142%). Trimethoprim had the highest apparent penetration rate constant of the three antibiotics but the smallest increase from normal to infected mucosa (44%), while the sulfamethoxazone apparent penetration rate constant increased from normal to infected mucosa by 55%.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Otitis Media Research Center, University of Minnesota, Minneapolis 55455.
authors.forename: G H
authors.initials: GH
authors.lastname: Jossart
authors.forename: G R
authors.initials: GR
authors.lastname: Erdmann
authors.forename: D G
authors.initials: DG
authors.lastname: Levitt
authors.forename: P
authors.initials: P
authors.lastname: Kucera
authors.forename: C T
authors.initials: CT
authors.lastname: Le
authors.forename: S K
authors.initials: SK
authors.lastname: Juhn
authors.forename: G S
authors.initials: GS
authors.lastname: Giebink
authors.forename: D M
authors.initials: DM
authors.lastname: Canafax
mesh_terms: D000658:Amoxicillin / Q000493:pharmacokinetics*; D000818:Animals; D002682:Chinchilla; D004432:Ear, Middle / Q000378:metabolism*; D010035:Otitis Media, Suppurative / Q000378:metabolism* / Q000382:microbiology; D011008:Pneumococcal Infections; D012996:Solutions; D013420:Sulfamethoxazole / Q000493:pharmacokinetics*; D014295:Trimethoprim / Q000493:pharmacokinetics*
chemical_list: D012996:Solutions; D000658:Amoxicillin; D014295:Trimethoprim; D013420:Sulfamethoxazole